Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab

Giorgia Bodini, Vincenzo Savarino, Laurent Peyrin-Biroulet, Chiara de Cassan, Pietro Dulbecco, Isabella Baldissarro, Valentina Fazio, Elisa Giambruno, Edoardo Savarino

Research output: Contribution to journalArticle

Abstract

Background: Whether therapeutic drug monitoring of biologic therapy can predict the efficacy of adalimumab to prevent postoperative Crohn's disease recurrence is unknown. Aim: To investigate whether adalimumab trough levels and anti-adalimumab antibodies correlate with endoscopic and clinical outcomes in a series of patients treated with prophylactic adalimumab monotherapy after resective surgery. Methods: Post hoc analysis of a randomized, mesalamine-controlled trial. Adalimumab trough levels and antibodies were analysed every 8 weeks for 2 years using an homogeneous mobility shift assay. Results: At two years, 1/6 patient had clinical recurrence and 1/6 patient had endoscopic and clinical recurrence. At baseline (9.5 vs. 14.4. mcg/mL) and during follow-up [7.5 (4.4-9.8) vs. 13.9 (8.9-23.6). mcg/mL, p

Original languageEnglish
Pages (from-to)1043-1046
Number of pages4
JournalDigestive and Liver Disease
Volume46
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Keywords

  • Adalimumab
  • Anti-tumour necrosis factor alpha antibodies
  • Crohn's disease
  • Post-surgical recurrence

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab'. Together they form a unique fingerprint.

  • Cite this

    Bodini, G., Savarino, V., Peyrin-Biroulet, L., de Cassan, C., Dulbecco, P., Baldissarro, I., Fazio, V., Giambruno, E., & Savarino, E. (2014). Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. Digestive and Liver Disease, 46(11), 1043-1046. https://doi.org/10.1016/j.dld.2014.07.171